149 related articles for article (PubMed ID: 30632279)
1. Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.
Critselis E; Rava M; Marquez M; Lygirou V; Chatzicharalambous D; Liapi P; Lichtinghagen R; Brand K; Cecchini L; Vlahou A; Malats N; Zoidakis J
Proteomics Clin Appl; 2019 Mar; 13(2):e1800148. PubMed ID: 30632279
[TBL] [Abstract][Full Text] [Related]
2. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
Kao SC; Kirschner MB; Cooper WA; Tran T; Burgers S; Wright C; Korse T; van den Broek D; Edelman J; Vallely M; McCaughan B; Pavlakis N; Clarke S; Molloy MP; van Zandwijk N; Reid G
Br J Cancer; 2016 Mar; 114(5):524-31. PubMed ID: 26889976
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis.
Guo W; Zhang M; Chen Y; Guo S
J Cancer Res Ther; 2017; 13(5):833-836. PubMed ID: 29237913
[TBL] [Abstract][Full Text] [Related]
5. Roles of SPARC in urothelial carcinogenesis, progression and metastasis.
Said N
Oncotarget; 2016 Oct; 7(41):67574-67585. PubMed ID: 27564266
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors.
Ma Y; Chen H; Ma H; Yao Z; Hu J; Ma J; Zhang X; Chen G; Liu Y
Saudi Med J; 2019 Aug; 40(8):755-765. PubMed ID: 31423511
[TBL] [Abstract][Full Text] [Related]
7. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
8. The role of SPARC expression in pancreatic cancer progression and patient survival.
Gundewar C; Sasor A; Hilmersson KS; Andersson R; Ansari D
Scand J Gastroenterol; 2015; 50(9):1170-4. PubMed ID: 25765175
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.
Ikuta Y; Nakatsura T; Kageshita T; Fukushima S; Ito S; Wakamatsu K; Baba H; Nishimura Y
Clin Cancer Res; 2005 Nov; 11(22):8079-88. PubMed ID: 16299239
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
12. SPARC is associated with gastric cancer progression and poor survival of patients.
Zhao ZS; Wang YY; Chu YQ; Ye ZY; Tao HQ
Clin Cancer Res; 2010 Jan; 16(1):260-8. PubMed ID: 20028745
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction.
Wang B; Chen K; Xu W; Chen D; Tang W; Xia TS
Mol Med Rep; 2014 Sep; 10(3):1461-8. PubMed ID: 24938427
[TBL] [Abstract][Full Text] [Related]
16. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
17. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.
Zhu A; Yuan P; Du F; Hong R; Ding X; Shi X; Fan Y; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B
Oncotarget; 2016 Nov; 7(47):76628-76634. PubMed ID: 27421134
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ on stereotactic biopsy of suspicious breast microcalcifications: Expression of SPARC (Secreted Protein, Acidic and Rich in Cysteine) can predict postoperative invasion.
Szynglarewicz B; Kasprzak P; Donizy P; Biecek P; Halon A; Matkowski R
J Surg Oncol; 2016 Oct; 114(5):548-556. PubMed ID: 27439354
[TBL] [Abstract][Full Text] [Related]
19. Humoral SPARC/osteonectin protein in plasma cell dyscrasias.
Turk N; Kusec R; Jaksic B; Turk Z
Ann Hematol; 2005 May; 84(5):304-10. PubMed ID: 15645230
[TBL] [Abstract][Full Text] [Related]
20. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.
Kaleağasıoğlu F; Berger MR
World J Gastroenterol; 2014 Oct; 20(40):14747-59. PubMed ID: 25356037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
